Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus R-ICE for relapsed or refractory diffuse large B-cell lymphoma
ISRCTN86607306Phase 2Active, not recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Event-free survival at 1 year. Started Jun 2022; status: active, not recruiting.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN86607306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86607306.